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in lifetime costs and utilities of $17,208 and 10.4124 QALYs compared with $16,780
and 10.4057 QALYs for prasugrel therapy. The ICER for clopidogrel was $63,840/
QALYs. The acceptability curve showed that prasugrel was not likely cost-effective
with 80% certainty at any WTP threshold. One-way sensitivity analyses (WTP
decision threshold: $100,000/QALY) showed that prasugrel is the most cost-effec-
tive strategy when probability of MI is increased by12%, probability of bleeding is
decreased by 24%, and disutility associated with MI is 0.1634. When only pa-
tients with variant CYP2C19 were considered, the ICER was found to be $2,313,333/
QALY for clopidogrel. CONCLUSIONS: Inconclusive results indicate that there is no
benefit in prescribing one therapy over the other for the entire patient population.
CYP2C19 polymorphism should be given consideration during the decisionmaking
process. For the base-case scenario, prasugrel therapywas the preferred strategy in
patients with variant CYP2C19.
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OBJECTIVES: To evaluate the cost-effectiveness of rivaroxaban compared with
dabigatran and enoxaparin for the prophylaxis of venous thromboembolism in
patients undergoing elective total hip replacement (THR) in the context of Russian
health care system.METHODS: A decision-tree model on the choice of regimens
for thromboprophylaxis after THR was adopted from the model, developed by
McCullagh et. al. (2009). Primary outcomes was mortality, occurrence of distal and
proximal DVT, rates of symptomatic PE. Incidence of gastrointestinal bleeding,
stroke and death was also included into the model. Delphi method was used to
determine typical practice and cost ofmanagement of DVT and PE. It was assumed
that patients with DVTwere treated for 90 days, patients with PE – for 180 days. All
patients in the model received thromboprophylaxis with one of the following reg-
imens: rivaroxaban dose of 10 mg/day orally for 31-39 days (RECORD 2); dabigatran
dose of 220 mg/day orally for 28-35 days (RE-NOVETE); enoxaparin dose of 40 mg/
day subcutaneously for 10-14 days (RECORD 2). Incremental cost-effectiveness ra-
tios (ICERs) were calculated. RESULTS: The cost of prophylaxis with enoxaparin
was 6991 USD, with dabigatran - 7076 USD, with rivaroxaban - 7147 USD. Although
rivaroxaban has more effectiveness in preventing DVT (0.016 vs. 0.082 vs. 0.045)
and PE (0.0012 vs. 0.005 vs. 0.004) than enoxaparin and dabigatran correspondingly.
ICER to prevent 1 case of deep vein thrombosis after THR in rivaroxaban versus
enoxaparin was 23.6 USD, and in dabigatran versus enoxaparin was 22.9 USD. ICER
to prevent 1 case of pulmonary thromboembolism after THR in rivaroxaban versus
enoxaparin was 556.7 USD, and in dabigatran versus enoxaparin was 850.3 USD.
CONCLUSIONS: Despite of higher cost of prophylaxis of DVT and PE with rivaroxa-
ban, comparing to enoxaparin and dabigatran, prophylaxis with rivaroxaban was
more effective with acceptable ICERs.
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OBJECTIVES: New medicines are launched based on a limited number of clinical
trials. Payers, providers, and patients base their utilization decisions on this infor-
mation. Furthermore, projected cost-effectiveness and real world cost-effective-
ness are moving targets that may differ greatly, especially early in the product life
cycle.We examine this divergence using clopidogrel, an antiplateletmedication for
preventing strokes and heart attacks, as a case study. METHODS: Using the Na-
tional Ambulatory Medical Care Survey (NAMCS) data from 1998 to 2008, we esti-
mate changes in the volume and distribution of patient prescriptions by age,
gender, and race. We combine these time trends with estimates from the
pharmacoeconomics literature on cost-effectivenessmeasured as cost per quality-
adjusted life year (QALYs). RESULTS: From 1998 (following approval in November
1997) to 2001, the average age of clopidogrel patients dropped from 77 to 70. Over
the same period, the percentage of patients who were under 54 years of age in-
creased from 0% to 13%. Comparing the real-world patient population to a pivotal
phase 3 trial also reveals a large difference in gender mix: 72% male in the trial vs.
45% in NAMCS in 1998. Similar trends were found for race: by 2008, patients were
much less likely to be white than in the trial—only 82% versus 95%. In 1999, 1.7
million office visits included a prescription for clopidogrel, 7.5 times as many as in
1998. By 2008, almost 16million prescriptionswerewritten—1.5 for every 100 office
visits. Adjusting for demographic mix, the estimated real-world CE improved be-
tween 2000 and 2001 by 16% ($25,000 per QALY vs. $21,000, respectively). From 1998
to 2008, the CE ratio fell by 23%. CONCLUSIONS: These results demonstrate that
cost-effectiveness projected at launch may provide only limited indication of the ul-
timate real-world impact, which improved substantially over time, in this example.
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OBJECTIVES: To evaluate and compared the long-term costs and outcomes of four
warfarin treatment strategies of CYP2C9, VKORC1, both CYP2C9 and VKORC1 gen-
otype-guided dosing, and standard warfarin dosing among nonvalvular VTE pa-
tients in the societal perspective. METHODS: A discrete event simulation model
was used to depict patients’ health states as the disease evolves with time, and
captured its associated costs (2007 U.S. dollars) and quality of life. Data was extrap-
olated with the criteria of including VTE patients of age 18 years on warfarin
with INR target of 2-3. Probabilities, costs and humanistic properties were obtained
from the literature, HCUP (NIS & SEDD), and the Medicare Reimbursement Sched-
ule databases. Sensitivity analysis was performed for uncertainty parameters in
the model. All costs and benefits were discounted at 3%. RESULTS: There was a
significant difference in the prevalence of bleeding complication between standard
anticoagulation (6.1%) and the genotype –guided of CYP2C9 and VKORC1 groups
(5.8%). The mean cost and QALYs per patients were $14,340 and 8.1251. The
genotype-guided warfarin anticoagulation strategies projected higher cost and
higher QALYs. However, considering the threshold of $100,000/QALY, VKORC1 gen-
otype-guided was indicated to be cost-effective among all strategies. Sensitivity
analysis demonstrated 25% of the replications of both CYP2C9 and VKORC1 geno-
type-guided strategy to be $100,000/QALY. CONCLUSIONS: This study showed
that testing for multiple genotypes of CYP2C9 and VKORC1 to guide warfarin anti-
coagulation therapy is not cost –effective in all population and that patient with
higher risk of complications are more likely to benefit from this new innovation.
For the genotype-guided test to be cost-effective in the population with VTE, the
cost of the test would have to be $400 or be restricted to patient at high risk for
bleeding complications (RR5.8).
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OBJECTIVES: The PLATO trial showed that in patients with acute coronary syn-
dromes (ACS) treatment with ticagrelor compared with clopidogrel significantly
reduced the rate of myocardial infarction (MI), stroke, or death from vascular
causeswithout a significant increase in the rate of overallmajor bleeding. Based on
clinical and health-economic data from PLATO the present study evaluates the
long-term cost-effectiveness of treating patients with ticagrelor based on the EU
label.METHODS: A two-part decision-analytic model, comprising a one-year deci-
sion tree and a long-termMarkovmodel, was constructed to estimate lifetime costs
and QALYs of treating ACS patients for one year with ticagrelor plus acetylsalicylic
acid (ASA) comparedwith clopidogrel plus ASA. Using individual-patient data from
PLATO, event rates, health-care costs (Swedish in base-case analysis), and QALYs
were estimated for the first year. For the second year onwards, necessary assump-
tions and external data sources were utilized to extrapolate quality-adjusted sur-
vival conditional onwhether a non-fatalMI, a non-fatal stroke or no event occurred
during the first year. A probabilistic analysis was performed and incremental cost-
effectiveness ratios are presented from a health-care perspective in 2010 prices. A
generic clopidogrel price of €0.17 ($0.23) per day, and a ticagrelor price range of €2.25
($3.00) to €3.50 ($4.65) per day were applied. RESULTS: Treatment with ticagrelor
was associated with a QALY gain of 0.13 compared with clopidogrel. The cost per
QALY gained with ticagrelor was in the range of €2,350 ($3,110) to €5,700 ($7,550)
compared with clopidogrel. Ticagrelor is likely to be cost-saving if proprietary
clopidogrel prices are applied. The results were consistent in major sub groups
across the broad ACS population. CONCLUSIONS: Based on clinical and health-
economic evidence from the PLATO study, treating a broad spectrum of ACS pa-
tients with ticagrelor for one year based on the European label is cost-effective
compared with clopidogrel.
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OBJECTIVES: Associated use of antithrombotics, antiplatelets and invasive strate-
gies in patients with non ST-segment elevation acute coronary syndromes (NSTE-
ACS) reduces cardiovascular events, however, with an increase in the risk of bleed-
ing. Clinical studies showed that fondaparinux is as effective as enoxaparin in
treating patients with NSTE-ACS, but with reduced risk of bleeding events. The
objective was to determine the cost-effectiveness of fondaparinux versus enoxa-
parin in patients with NSTE-ACS in Brazil from the perspective of the Brazilian
Ministry of Health (MoH). METHODS: An analytic decision tree model was con-
ducted to estimate the resultant costs and consequences of the targeted therapies
in patients with NSTE-ACS. Model input data derived from the OASIS-5 study
(N20,078 NSTE-ACS patients randomized to fondaparinux or enoxaparin). The
analyzed outcome was a composite of cardiovascular events (i.e., death, acute
myocardial infarction, stroke, and major bleedings). Model time horizon was 9, 30,
and 180 days post-NSTE-ACS. Direct costs of NSTE-ACS events and treatments
were computed (i.e., drugs, coronary angiography, myocardial revascularization,
percutaneous intervention - PCI, hospitalizations, etc.). Costs were expressed in
2010 Brazilian currency (1BRL0.59USD). Univariate andmultivariate (Monte Carlo)
analyses tested model robustness. RESULTS: At day 9, the average cost per patient
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treated was 2,575 for fondaparinux and 2,688 for enoxaparin. Over 65% of total
costs were attributed to the invasive treatment (PCI and revascularization). Drug
costs (in-hospital therapies) accounted for 10% (fondaparinux) and 12% (enoxa-
parin) of total costs. The estimated rates of cardiovascular events were 7.3% and
9.0% for fondaparinux and enoxaparin, respectively. Results kept unchanged on
days 30 and 180 post-NSTE-ACS. Sensitivity analysis confirmed base-case results.
CONCLUSIONS: Fondaparinux was dominant over enoxaparin (lower costs, better
long-term benefits). The budget impact after 5 years of anticoagulant substitution
(at 20% constant adoption rate per year) could reach 90 million BRL in savings for
the Brazilian MoH and healthcare system.
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OBJECTIVES: The objective of this analysis was to estimate the cost effectiveness of
commonly used antiarrhythmic agents for the treatment of supraventricular tachy-
cardia (SVT) and intraoperative/ postoperative tachycardia and hypertension.
METHODS: A decision tree model was built to examine the cost effectiveness of
esmolol, metoprolol, diltiazem and amiodarone for the treatment of SVT and in-
traoperative and postoperative tachycardia and hypertension from a hospital per-
spective. The default pharmacy costs in themodelwere based on publicly available
wholesale acquisition costs (WAC). Literature based values were used for the rates
and medical costs of adverse cardiac events including myocardial infarction,
stroke, hypotension, bradycardia, and ischemia. The primary efficacy parameter,
rate of successful heart rate control, was based on literature values. The outcome
was the cost per successful heart rate control with incremental cost effectiveness
ratios (ICERs) calculated. No discountingwas applied due to the short time frame of
the analysis. For the probabilistic sensitivity analysis, a Monte Carlo simulation
consisting of 1,000 simulations was conducted to test the joint uncertainty of all
modeling parameters simultaneously. RESULTS: The total cost of therapy was
$1,250.82, $2,630.19, $2,280.21, and $1,555.14 for esmolol,metoprolol, diltiazemand
amiodarone, respectively. The rate of successful heart rate control was 90% (es-
molol), 64% (metoprolol), 90% (diltiazem) and 74% (amiodarone). The cost per suc-
cessful heart rate control was $1,389.80 (esmolol), $4,109.67 (metoprolol), $2,533.57
(diltiazem), and $2,101.54 (amiodarone). The ICER of esmolol dominated meto-
prolol, diltiazem and amiodarone. In the probabilistic sensitivity analysis, esmolol
was the most cost-effective antiarrhythmic in 99.6% of simulations. One-way sen-
sitivity analyses showed the model was most sensitive to the cost of hypotension
and bradycardia. CONCLUSIONS: In this model, esmolol was the least costly and
most effective antiarrhythmic. Esmolol is cost-effective in comparison with meto-
prolol, diltiazem and amiodarone for the treatment of SVT and intraoperative/
postoperative tachycardia and hypertension.
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OBJECTIVES: Patients after major orthopedic surgery on the joints of the lower
extremities require an effective thromboprophylaxis to prevent deep vein throm-
bosis (DVT) and pulmonary embolism (PE). Objective of this study was to evaluate
the cost-effectiveness of rivaroxaban compared with dabigatran and enoxaparin
for the prophylaxis of venous thromboembolism in patients undergoing elective
total knee replacement (TKR) in the context of Russian health care system.
METHODS: A decision-tree model on the choice of regimens for thromboprophy-
laxis after TKR was adopted from the model, developed by McCullagh et. al. (2009).
Primary outcomes was mortality, occurrence of distal and proximal DVT, rates of
symptomatic PE. Incidence of gastrointestinal bleeding, stroke and death was also
included into themodel. Delphimethodwas used to determine typical practice and
cost of management of DVT and PE. It was assumed that patients with DVT were
treated for 90 days, patients with PE – for 180 days. All patients in themodel receive
thromboprophylaxis with one of the following regimens: rivaroxaban dose of 10
mg/day orally for 10-14 days (RECORD 3); dabigatran dose of 220 mg/day orally for
12-15 days (RE-MODEL); enoxaparin dose of 40 mg/day subcutaneously for 10-14
days (RE-MODEL). Incremental cost-effectiveness ratios (ICERs) were calculated.
Analyses was made from state health care point of view. RESULTS: The cost of
prophylaxis with rivaroxaban was 5621 USD (dominant technology), with enoxa-
parin - 5657 USD, with dabigatran - 5763 USD. Rivaroxaban has more effectiveness
in preventing DVT (0.096 vs. 0.36 vs. 0.36) and PE (0.00 vs. 0.001 vs. 0.00) than
enoxaparin and dabigatran correspondingly. CONCLUSIONS: Results of modeling
have shown that rivaroxaban is dominant technology for prevention of venous
thromboembolism after total knee replacement comparing to enoxaparin and dab-
igatran in the scope of Russian health care system.
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OBJECTIVES: Atrial fibrillation has been estimated to affect as many as 2.3 million
Americans, making it the second most common cardiovascular condition in the
United States. Atrial fibrillation has been found to increase patient’s risk of stroke
by 5-fold. We sought to calculate the projected total treatment costs, quality-ad-
justed survival and cost-effectiveness of dabigatran and adjusted-dosewarfarin for
stroke prevention in patients with atrial fibrillation. METHODS: This three-state
Markov transitionmodel (healthywith atrial fibrillation, disability, and death) sim-
ulated the treatment costs, quality-adjusted survival and cost-effectiveness of dab-
igatran 150 mg twice daily and adjusted-dose warfarin (international normalized
ratio of 2-3) for stroke prevention in atrial fibrillation. Our base-case consisted of a
hypothetical cohort of65 year old patients with atrial fibrillation, amoderate risk
of stroke (CHADS21) and no contraindications to anticoagulation therapy. The
parameters used in the model were adopted from the literature research, Cost-
effectiveness was calculated over a patient’s lifetime and using a societal perspec-
tive (excluding indirect costs). One-way and threshold sensitivity analyses were
performed on all relevant variables. RESULTS: The mean quality-adjusted life ex-
pectancy of simulated patients was 12.9 and 12.2 years for those receiving dabiga-
tran and warfarin. Total lifetime treatment costs were $146,649 and $118,904. The
incremental cost-effectiveness ratio was $40,580. Upon one-way sensitivity analy-
sis, our conclusions were found to be sensitive to changes in dabigatran cost and
the differential efficacy of the two strategies. Threshold sensitivity analysis further
revealed that daily dabigatran costs greater than $13 per day and differential effi-
cacy between the two strategies of less than 0.15% per year resulted in incremental
cost-effectiveness ratios greater than $50,000 per quality-adjusted life year gained.
CONCLUSIONS: Our analysis suggested that dabigatran is cost-effective for stroke
prevention in atrial fibrillation; however, this conclusion was sensitive to changes
in dabigatran costs and the antithrombotic efficacy of the two treatment strategies.
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OBJECTIVES: The cost-effectiveness of a drug is often evaluated at a single point in
time, yet costs, effects, or relevant comparators may change over the product life
cycle. This study models the cost-effectiveness of atorvastatin from product
launch in 1997 through 2011 and into the future.METHODS:We model the yearly
cost-effectiveness of atorvastatin compared to its major competitor simvastatin
from 1997 to 2030 from a US payer point of view. Key events include the entry of
generic simvastatin in June 2006 and the expected entry of generic atorvastatin in
November 2011. Estimates for incremental costs (in USD) and effects (in QALYs) for
primary and secondary prevention of cardiovascular events are taken from previ-
ous literature and adjusted for drug price changes over time. Total statin use esti-
mates are derived from NHANES. Sensitivity analysis examines variation in study
parameters including drug prices, indication use, and discount rates. RESULTS:
Assuming increasing statin use over time (with a mean of 1m new users per year)
and a 3% discount rate, the cumulative incremental cost-effectiveness ratio (ICER)
for atorvastatin vs. simvastatin ranges from cost saving at release to amaximumof
$45,066 per QALY after six years of generic simvastatin in 2012. Over the full mod-
eled life cycle (1997-2030), the cumulative ICER of atorvastatin is $20,331 per QALY.
Results were similar in sensitivity analysis. CONCLUSIONS: The ICER of atorvasta-
tin varies across the product life cycle, rising during the period between generic
simvastatin entry and generic atorvastatin entry, and declining afterwards. Over
its life cycle, atorvastatin is associatedwith a cumulative ICER of $20,331 per QALY,
with a maximum of $45,066 per QALY.
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COST-EFFECTIVNESS STUDY OF CITICOLINE IN PATIENTS WITH ACUTE
ISCHEMIC STROKE IN RUSSIA
Vorobyev P, Bezmelnitsyna L, Borisenko O
Russian Society for Pharmacoeconomics and Outcomes Research, Moscow, Russia
OBJECTIVES:Cerebrovascular diseases are on the second place among all causes of
death in Russia. Neuroprotective therapy is one of themain approaches of therapy
in patientswith acute ischemic stroke in Russia despite the absence of this group of
medicines in the recommendations of national standard of care in stroke (GOST R
200). The objective of this research was to evaluate cost-effectiveness ratio for the
use of citicolin (a neuroprotective agent widely used in some EU countries, South
Korea, Russia and some other countries) in patients treated according to the na-
tional standard of care in stroke (GOST R 200).METHODS: The data on the efficacy
of citicolin in patients with acute ischemic stroke were extracted from pooling
analysis of clinical trials “Oral citicolin in acute stroke” (Davalos A. et al., 2002) The
clinical effect was measured as global recovery index (proportion of patients with
full recovery during 3 months). Cost of treatment with citicolin and cost-effective-
ness ratio (CER) were calculated from the point of view of the Russian state health
care system. RESULTS: According to the results of the above mentioned pooling
analysis, the use of citicoline in stroke patients was associated with significantly
greater rate of recovery than placebo (OR,1.33; 95% CI, 1.10 to 1.62). Costs of treat-
ment of acute ischemic stroke according to recommendations of the national stan-
dard plus citicolin was 1 715.5 USD per 3 months. Costs of the treatment without
citicolin was 1 289 USD per 3 months. CER (i.e. direct costs per one fully recovery
patient) treated with citicolin and placebo were 6 354 USD and 6 384 USD respec-
tively. Incremental CER was 6 264 USD. CONCLUSIONS: According to the applied
model a treatment, citicolin appeared to demonstrate its clinically efficacy and
cost-effectiveness in treatment of the patients with acute ischemic stroke, com-
pared to placebo.
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